Integrated management of atrial fibrillation with digital health support: a pooled analysis of individual participant data from the mAFA-II and MIRACLE-AF trials.
Gregory Y H Lip, Yang Chen, Mingfang Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled individual participant data analysis combined two prospective randomised trials of adults with atrial fibrillation: mAFA-II, which delivered ABC pathway care through a mobile app, and MIRACLE-AF, which used village doctors supported by telehealth. Among 4,363 patients followed for a mean of 0.8 (SD 0.4) years, the composite of death, stroke, heart failure, acute coronary syndrome, or major bleeding occurred in 7.5%. Integrated care was associated with a lower risk of the composite than usual care (adjusted hazard ratio 0.72; 95% confidence interval 0.56-0.93), with benefit primarily driven by fewer heart failure/acute coronary syndrome events.
Key findings
- The primary composite endpoint occurred in 329 of 4,363 patients (7.5%) during follow-up.
- ABC pathway-based care was associated with lower primary endpoint risk than usual care (adjusted hazard ratio 0.72; 95% confidence interval 0.56-0.93).
- The reported benefit was primarily driven by reductions in heart failure/acute coronary syndrome events rather than classical AF-specific outcomes.
- Effects on the primary endpoint were directionally consistent across the two trials; subgroup analyses suggested potential effect modification.
Why it matters
The findings support the potential value of coordinated, holistic AF management delivered through different digital and community-based models. The apparent contribution of heart failure and acute coronary syndrome outcomes also highlights that integrated care may affect broader cardiovascular risk, not only stroke-related outcomes. The pooled analysis adds evidence across two care settings, while leaving the best context for implementation to be established.
What to keep in mind
Follow-up was relatively short (0.8 [SD 0.4] years), and the pooled analysis combined two trials with different delivery models. Subgroup analyses suggested potential effect modification.